Table 2.
DHEA, SHBG, and T Values at Baseline and After 2 Years of Supplementation With DHEA or T
| Younga |
Elderly Females |
Elderly Males |
|||||
|---|---|---|---|---|---|---|---|
| Hormone Values | F | M | Placebo | DHEA | Placebo | DHEA | T |
| SHBG, nmol/L | |||||||
| Baseline | 72.2 (45.6, 144.5)b | 23.4 (19, 29)c | 50 (36.6, 73.8) | 52.4 (34.9, 71.4) | 41.7 (35.1, 50.8) | 33.1 (28.5, 36.8) | 36.8 (30.2, 40.8) |
| Year 2 | 54.2 (37, 67.7) | 37.8 (24.9, 45.9) | 41.2 (36.6, 49.4) | 31.2 (26.4, 36.6) | 36.6 (31.3, 44.4) | ||
| Changed | −1 (−8.5, 5.4) | −13.6 (−27.2, −4.5)e | 0.4 (−5, 6) | −2.4 (−5, 2.6)f | −0.2 (−5.1, 3.4)f | ||
| DHEAS, μg/mL | |||||||
| Baseline | 1.4 (1, 2)b | 2.75 (1.9, 3.7)c | 0.3 (0.3, 0.4) | 0.3 (0.3, 0.5) | 0.62 (0.42, 1) | 0.65 (0.4, 0.9) | 0.6 (0.3, 0.9) |
| Year 2 | 0.3 (0.3, 0.4) | 3.66 (2.7, 6) | 0.55 (0.3, 0.8) | 3.96 (3.1, 6.3) | 0.5 (0.3, 0.7) | ||
| Changed | 0 (−0.04, 0) | 3.9 (2.9, 5)g | −0.1 (−0.2, 0.02) | 3.9 (2.8, 5.3)e | −0.07 (−0.17, 0) | ||
| Total T, ng/dL | |||||||
| Baseline | 543 (470, 675)c | 387 (294, 460) | 373.5 (254, 440) | 362 (295, 459) | |||
| Year 2 | 383 (331, 527) | 348 (276, 451) | 494 (421, 637) | ||||
| Changed | 24 (−14.5, 67.5) | 1.5 (-23, 32.8) | 111 (39, 252)e | ||||
| Bioavailable T, ng/dL | |||||||
| Baseline | 174.4 (125, 238)c | 52.7 (43.6, 63.6) | 63.5 (51.6, 76.5) | 57.1 (45.7, 65.7) | |||
| Year 2 | 52.9 (38.6, 65.1) | 65.3 (53.4, 88.1) | 82.8 (65, 115.1) | ||||
| Changed | −0.78 (−7.7, 11.6) | 3.5 (−5.7, 19) | 30.5 (−0.9, 62.5)h | ||||
Abbreviations: F, female; M, male. Data are expressed as median (interquartile range).
a
Thirty-eight healthy young women and 37 healthy young men baseline hormonal values obtained compared with values in the elderly groups.
b
P < .001 young females vs elderly females at baseline.
c
P < .001 young males vs elderly males at baseline.
d
Change in hormone levels (year 2 − baseline).
e
P < .001 vs placebo.
f
No significant change compared with placebo.
g
P < .0001 vs placebo.
h
P < .01 vs placebo.